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The Biobank Act as a Route to Responsible Research:
A First Step for Taiwan?
Ching-Yi Liu*
In recent years, biobanks have been established
around the world to monitor the health status 
of participants over time, to assess the natural 
occurrence and progression of common diseases.1
Therefore, it is not surprising to learn that tradi-
tional ethical and legal issues such as informed
consent, privacy protection, data security, non-
discrimination, autonomy and self-determination
have occupied a central place in the regulatory
debates on biobanks.2 In the midst of controversies
raised by human rights organizations and abo-
riginal rights groups,3 Taiwan’s Human Biobank
Management Act (“the Act”) was passed by the
Legislative Yuan on January 7, 2010 and came into
effect on February 3 in the same year. While the Act
addresses the absence of biobank regulations, it
could also have a marked impact upon local bio-
medical research communities. It is therefore nec-
essary to address the coverage of the Act, which is
one of the key issues surrounding this legislation.
The Act was originally designed to regulate
the establishment and management of biobanks;
mainly, the collection and storage of human bio-
logical samples and associated data. According to
Article 3(4), a regulated biobank that contains
biological specimens from human subjects, along
with related information and data, should also
have the following two characteristics: (1) it should
provide for biometrics-related research, which is
population- or specific-group-based; and (2) it
should be maintained with linkable data. In other
words, in addition to the regulation of biobank-
ing, the Act also regulates biomedical research
activities that originate from the use of biological
specimens and data from biobanks.
Biomedical research that does not use biologi-
cal specimens or data from biobanks is not covered
by the Act. Any specific research in which biologi-
cal specimens and associated data are collected
and then destroyed or delinked upon completion
of the research is not deemed to be a biobanking
project. On the contrary, archive collections with-
out a defined research purpose are targets of the
Act. This includes collections that have biologi-
cal specimens and data collected for a general,
undefined purpose other than immediate research
use, as well as those maintained by many univer-
sity laboratories from earlier studies.
Among other things, it is worthwhile to note
that Article 29 does give rise to a question regarding
©2011 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Graduate Institute of National Development, National Taiwan University College of Social Science, Taipei, Taiwan.
Received: November 4, 2010
Revised: December 14, 2010
Accepted: January 5, 2011
*Correspondence to: Dr Ching-Yi Liu, National Taiwan University College of Social Science,
Taipei 106, Taiwan.
E-mail: cy1117@ms17.hinet.net
the precise coverage of the Act. This Article pro-
vides that “Articles 6, 15, 16 and 20 shall apply,
where appropriate, to the collections and use 
of biological specimens used in biomedical re-
search which is not based on population groups
or specific groups, unless otherwise provided.”
Under this Article, some specimen collections or
uses that do not fit into the definition of a biobank-
ing project or biobank-related research are still
subject to Articles 6, 15, 16 and 20 of the Act.
Article-29-type research only refers to biomedical
research that is not based upon populations or
specific groups, therefore, it is certainly an exag-
geration to say that the Act governs all kinds of
medical research. However, it does raise a difficult
question as to how and to what extent Articles 6,
15, 16 and 20 are applicable to Article-29-type
biomedical research.
Clearly, the application of Article 6, which regu-
lates consent to biobank research, to Article-29-
type biomedical research does not give rise to
any difficulties. Article 6 of the Act requires that
the collection of biological specimens be con-
ducted in compliance with medical ethics and
research ethics, as well as undertaken with legally
valid, written informed consent from participants.
However, the application of Article 15 to Article-
29-type research seems troublesome, because the
former states that “biological specimens of the
Biobank, other than the derivatives, shall not 
be exported” and “any international transmission
of Biobank data or the export of any derivatives
mentioned in the preceding Paragraph shall be
submitted to the Competent Authority for ap-
proval” [Articles 15(1) and 15(2)]. In the case of
specimen collection and uses limited to specific
population-based research, such as disease-specific
clinical trials, Article 15 is inapplicable because it
is not a biobanking project nor biobank-related
or Article-29-type research. However, for non-
population-based biomedical research, the prohi-
bition on exporting biological specimens might
become a new obstacle for those who need some
freedom to transfer biological specimens in-
ternationally for a specific research purpose. In
other words, this new legal approach regarding
exportation of biological specimens is to some
extent at odds with biomedical research practices.
Some minor revisions of Articles 15 and 29 might
be unavoidable in the near future.
A more careful reading of Article 20, which
requires biobank-related and Article-29-type re-
search to follow the “biomedical research pur-
poses only” principle, also raises uncertainties as
to how and under which criteria ethics commit-
tees, at the biobank operator and Department 
of Health levels, will determine whether medical
research is qualified for exemption from Article
20. Article 20 provides that “any use of biological
specimens, derivatives and relevant data and in-
formation in the Biobank shall not be used for
purposes other than biomedical research. Medical
research approved in accordance with Article 5,
Paragraph 3 hereof shall not be subject to this
rule.” Is it the true intent of the legislature to au-
thorize the ethics committees to exercise a general
consent power on behalf of the participants?4 If
so, what are the conditions and limitations that
should be taken into account when the ethics
committees grant such permission? Such questions,
along with the obligations imposed by Article 30
that require corrective actions in accordance with
the Act for pre-existing biobanks, present a seri-
ous challenge for ethical governance of medical
institutions and researchers. Article 30 provides
that for any biobank established prior to the en-
forcement of the Act, its operator shall destroy
and may not reuse any and all biological speci-
mens and related data and information, if the
operator fails to finalize the necessary corrective
actions in accordance with the Act within 1 year
after the Act takes effect.
In conclusion, this new Act does add some-
thing meaningful to the incomplete legal land-
scape for the regulation of biomedical research
in Taiwan. However, it is fair to say that the ex-
tended coverage of the Act, enabled by Article 29
and the ambiguous definition of biomedical re-
search in Article 3(3), has created difficulties that
are not easily resolvable through any reasonable
interpretation of the above Articles. The interpre-
tative difficulties will soon emerge as one of the
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major regulatory uncertainties for local biomed-
ical research communities. On balance, as the Act
was originally designed to regulate biobanking
and biobank-related research, it is a more sensible
proposal to have this Act play a constrained role.
Although it is now time for medical research in-
stitutions to stop complaining about the burden
imposed by the Act, and to figure out a practical
model for maintaining and overseeing their pre-
existing biobanks, it is also urgent for the legisla-
ture to pass a general law to regulate biomedical
research and excuse the Biobank Act from its cur-
rent awkward role as soon as possible.
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